₹215.31
▲ +0.75 +0.35%
As of 27 Jul 2026 · delayed
NSE Listed
Laxmi Dental Limited (LAXMIDENTL)
Volume: 1,45,098Avg Vol 1W: 1,69,861.6Avg Vol 1M: 1,22,728.452W Range:₹155.88₹472.2
Key Ratios
Checked 1d agoMarket Cap₹1,198 Cr
Current Price₹215.31
Previous Close₹214.56
High / Low (52w)₹472.2 / ₹155.88
Volume1,45,098
Avg Vol (1W)1,69,861.6
Avg Vol (1M)1,22,728.4
Stock P/E119.13
Book Value₹44.28
Dividend Yield0%
ROE13.7%
ROA9%
Revenue (TTM)₹242 Cr
Revenue Growth23.5%
Profit Margin10.7%
Total Debt₹11 Cr
Shares Outstanding5 Cr
Face Value₹2
EPS (TTM)₹1.83
P/B4.92
Debt / Equity0.05
50 DMA₹224.97
200 DMA₹231.01
Day change+0.35%
Price Chart
₹215.31▼ 49.43% · 1Y
2025-07-292026-07-27
20-day avg volume: 1.2L shares
Pros
- Company is almost debt-free.
- Revenue grew 59% YoY.
Cons
- Company is loss-making at the latest annual result.
- Stock trades at a high P/E of 119.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹60 Cr | ₹57 Cr | ₹62 Cr | ₹61 Cr | ₹66 Cr | ₹72 Cr | ₹66 Cr | ₹74 Cr |
| EBITDA | ₹11 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹10 Cr | ₹10 Cr | ₹5 Cr | ₹11 Cr |
| Net Profit | ₹17 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹8 Cr | ₹9 Cr | ₹2 Cr | ₹10 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹42 Cr | ₹43 Cr | ₹43 Cr | ₹242 Cr | ₹50 Cr | ₹54 Cr | ₹48 Cr | ₹56 Cr |
| EBITDA | ₹3 Cr | ₹4 Cr | ₹7 Cr | ₹30 Cr | ₹9 Cr | ₹7 Cr | ₹4 Cr | ₹7 Cr |
| Net Profit | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹32 Cr | ₹8 Cr | ₹7 Cr | ₹-2 Cr | ₹7 Cr |
| EPS | — | — | — | 6.05 | — | — | — | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Total Assets | ₹106 Cr | ₹106 Cr | ₹103 Cr | ₹97 Cr | ₹135 Cr | ₹285 Cr |
| Total Liabilities | ₹57 Cr | ₹61 Cr | ₹80 Cr | ₹77 Cr | ₹90 Cr | ₹76 Cr |
| Equity | ₹49 Cr | ₹44 Cr | ₹23 Cr | ₹19 Cr | ₹45 Cr | ₹209 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating | ₹10 Cr | ₹10 Cr | ₹-2 Cr | ₹15 Cr | ₹9 Cr | ₹46 Cr |
| Investing | ₹-18 Cr | ₹-9 Cr | ₹3 Cr | ₹-9 Cr | ₹-11 Cr | ₹-29 Cr |
| Financing | ₹6 Cr | ₹0 Cr | ₹-4 Cr | ₹-1 Cr | ₹-3 Cr | ₹111 Cr |
| Free Cash Flow | ₹10 Cr | ₹10 Cr | ₹-2 Cr | ₹15 Cr | ₹9 Cr | ₹46 Cr |
Shareholding
Promoter 41.8% Institutions 40.99% Public 17.21%
Efficiency & Working Capital
ROCE17.6%
Interest Coverage5
Dividend Payout—
Debtor Days56 d
Inventory Days28 d
Payable Days49 d
Cash Conversion Cycle36 d
Working Capital Days84 d
Shareholding Details
As of 2026-06-30
Promoter41.8%
FII30.1%
DII10.9%
Institutions41%
Public17.2%
Promoter Pledge0%
No. of Shareholders36,937
Shareholding Pattern
Quarterly — figures in %. Latest 9 quarters.
| Period | Sept 2024 | Jan 2025 | Jan 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Promoters | 86.6% | 41.7% | 41.7% | 41.7% | 41.7% | 41.7% | 41.7% | 41.8% | 41.8% |
| FIIs | 0% | 7.1% | 29.5% | 34.2% | 33.6% | 32.4% | 32.5% | 31.2% | 30.1% |
| DIIs | 0% | 15.2% | 12.1% | 12.9% | 14.3% | 11.8% | 10.8% | 10.5% | 10.9% |
| Public | 13.4% | 36% | 16.7% | 11.2% | 10.4% | 14.1% | 15% | 16.5% | 17.2% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 13 | 54,533 | 54,533 | 29,482 | 27,957 | 37,909 | 38,635 | 38,161 | 36,937 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Orbimed Asia Ii Mauritius Limited | Public Shareholding | 22.4% | 1.23 Cr |
| Rajesh Vrajlal Khakhar | Shareholding of Promoter and Promoter Group | 17% | 93,17,526 |
| Sameer Kamlesh Merchant | Shareholding of Promoter and Promoter Group | 15.8% | 86,98,111 |
| Jigna Rajesh Khakhar | Shareholding of Promoter and Promoter Group | 7.8% | 43,07,444 |
| Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund | Public Shareholding | 4.7% | 25,71,551 |
| Goldman Sachs Funds - Goldman Sachs India Equity Portfolio | Public Shareholding | 3.5% | 19,23,240 |
| Amrish Desai | Public Shareholding | 2% | 11,07,710 |
| Parag Jamnadas Bhimjiyani | Public Shareholding | 2% | 11,07,710 |
| Hdfc Mutual Fund - Hdfc Pharma And Healthcare Fund | Public Shareholding | 1.4% | 7,55,253 |
| Eastspring Investments - Asia Growth Opportunities Equity Fund | Public Shareholding | 1.2% | 6,77,898 |
| Ashoka India Equity Investment Trust Plc | Public Shareholding | 1.1% | 6,20,314 |
| Uti-healthcare Fund | Public Shareholding | 1.1% | 5,98,666 |
| Kunal K Merchant | Shareholding of Promoter and Promoter Group | 0.9% | 5,06,510 |
| Dharmesh Bhupendra Dattani | Shareholding of Promoter and Promoter Group | 0.2% | 1,34,518 |
| Hasmukh Vrajlal Khakhar | Shareholding of Promoter and Promoter Group | 0% | 11,280 |
| Parth Rajesh Khakhar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Siddhi Rajesh Khakhar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Leelaben Vrajlal Khakhar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sanjay Vrajlal Khakhar | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Rupal Parag Bhimjiyani | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sonal A. Desai | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Bhavna Bhupendra Dattani | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Bhavi Sameer Merchant | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Yuvraj Merchant | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Rajveer Merchant | Shareholding of Promoter and Promoter Group | 0% | 0 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Rajesh Vrajlal Khakhar | Chairman & Exec. Director | 2025 |
| Sameer Kamlesh Merchant | ED / MD / CEO / Promoter | 2025 |
| Anjana Grewal | Independent Non Exe. Director | 2025 |
| Devesh Ghanshyam Chawla | Independent Non Exe. Director | 2025 |
| Rajesh Shashikant Dalal | Independent Non Exe. Director | 2025 |
| Anil Tilakraj Arora | Non-Exec & Non-Independent Dir | 2025 |
| Nupur Joshi | Company Sec. & Compli. Officer | 2025 |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹112 Cr | 66.4% |
| Foreign countries | ₹57 Cr | 33.6% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 13 | 11 | 11 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 86 | 0 | 26 | 7 | 10 | 131 |
| 2025 | 52 | 0 | 24 | 5 | 10 | 91 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
Insider / Designated-Person Trades
4 recent disclosure(s)
SAMEER KAMLESH MERCHANTAcquisition · 17,179
SAMEER KAMLESH MERCHANTAcquisition · 15,000
RAJESH VRAJLAL KHAKHARAcquisition · 11,000
MR. RAJESH VRAJLAL KHAKHARAcquisition · 12,000
Substantial Acquisitions (SAST)
2 disclosure(s)
Market23/02/2026 · 11,000
Market20/02/2026 · 12,000
Company Information
Incorporated2004
ChairmanRajesh Vrajlal Khakhar
AuditorMSKA & Associates
Investor Email[email protected]
📍 No.103 Akruti Arcade JP Road, Andheri West, Mumbai, Maharashtra, 400058
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search